Glaxosmithkline Stock News

GSK, which hopes to start ground-breaking trials as soon as next summer, will provide an update to the City on its potential cure for the disease.

Mcdonald Partners LLC boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 17.0% in the third quarter, Holdings Channel reports. The institutional investor owned 9,688 shares of the pharmaceutical companys stock after acquiring an additional 1,407 shares during the quarter. Mcdonald Partners LLCs holdings in GlaxoSmithKline were worth $370,000 as of its most recent filing with []

Berenberg Bank restated their buy rating on shares of GlaxoSmithKline (NYSE:GSK) in a research note published on Wednesday morning, The Fly reports. GSK has been the subject of a number of other reports. JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline in a report on Monday, November 1st. UBS Group reaffirmed []

Koshinski Asset Management Inc. increased its position in GlaxoSmithKline plc (NYSE:GSK) by 49.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 8,844 shares of the pharmaceutical companys stock after acquiring an additional 2,929 shares during the period. Koshinski Asset Management Inc.s holdings in GlaxoSmithKline were worth $338,000 as of its most recent SEC []

GlaxoSmithKline plc (NYSE:GSK) Stock analysts at SVB Leerink upped their FY2021 earnings per share (EPS) estimates for GlaxoSmithKline in a report issued on Tuesday, November 23rd. SVB Leerink analyst G. Porges now expects that the pharmaceutical company will earn $3.23 per share for the year, up from their previous forecast of $3.12. SVB Leerink [] The post SVB Leerink Analysts Increase Earnings Estimates for GlaxoSmithKline plc (NYSE:GSK) appeared first on ETF Daily News .

GlaxoSmithKline plc (LON:GSK) insider Hal Barron bought 2,422 shares of the companys stock in a transaction on Monday, November 22nd. The shares were bought at an average cost of GBX 2,065 ($26.98) per share, for a total transaction of £50,014.30 ($65,344.00). GSK stock opened at GBX 1,540 ($20.12) on Friday. The firm has a market []

Global Allergic Rhinitis Treatment Market Allergic rhinitis is the characteristic response to localized IgE-mediated inflammation that is triggered by exposure to an aeroallergen to which the individual is sensitized. Allergic rhinitis is further differentiated on the basis of aeroallergens that can

The "Antiparasitic Drugs" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Antiparasitic Drugs Industry presents a market overview, product details, classification, and

GlaxoSmithKline (LON:GSK) had its target price lifted by Berenberg Bank from GBX 1,540 ($20.12) to GBX 1,630 ($21.30) in a research note released on Monday, Analyst Ratings Network reports. The brokerage currently has a buy rating on the stock. A number of other equities analysts have also recently weighed in on the stock. Jefferies Financial []

The Live Vaccines Market Report 2021-2027 provides global market size, regional and national level market size, market segment growth, market share, competitive landscape, sales analysis, influence of domestic and global market participants, and value chain Detailed analysis of optimization, trade

In todays recent session, 1.19 million shares of the GlaxoSmithKline plc (NYSE:GSK) have been traded, and its beta is 0.73. Most recently the companys share price was $41.49, and it changed around -$0.11 or -0.27% from the last close, which brings the market valuation of the company to $102.58B. GSK at last check was trading GlaxoSmithKline plc (NYSE: GSK) Could See Prices Soar In The Coming Months Read More »

Jacobs & Co. CA raised its stake in GlaxoSmithKline plc (NYSE:GSK) by 6.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 198,675 shares of the pharmaceutical companys stock after purchasing an additional 12,672 shares during the period. Jacobs & Co. CAs holdings []

San Diego-based company plans to develop medications for neurological disorders Related Stocks: NBIX , SOLTF , LLY , PFE , MRK , BMY , AZN , GSK , AMGN , SNY , FRA:SNY , STU:SNY ,

Complete study of the global Penicillin and Streptomycin market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of